Shares of Immunic, Inc. (NASDAQ:IMUX – Get Free Report) have received an average rating of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $11.60.
Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Thursday, May 1st. Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. William Blair reiterated an “outperform” rating on shares of Immunic in a report on Friday, May 16th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Wednesday, June 25th. Finally, B. Riley reiterated a “buy” rating and set a $5.00 price target (down from $6.00) on shares of Immunic in a report on Friday, May 23rd.
Read Our Latest Analysis on Immunic
Institutional Trading of Immunic
Immunic Stock Up 2.2%
Shares of NASDAQ:IMUX opened at $0.73 on Friday. The firm has a market cap of $69.85 million, a P/E ratio of -0.59 and a beta of 1.49. Immunic has a 12-month low of $0.56 and a 12-month high of $2.11. The business has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $0.99.
Immunic (NASDAQ:IMUX – Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). As a group, equities research analysts expect that Immunic will post -0.94 EPS for the current year.
About Immunic
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Recommended Stories
- Five stocks we like better than Immunic
- Investing In Preferred Stock vs. Common Stock
- 3 Defense Leaders Set to Gain From Rising Military Spend
- What Investors Need to Know to Beat the Market
- Why the Schwab Dividend ETF Rallied—and Can It Keep Climbing?
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 06/30 – 07/04
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.